·Î±×ÀΠ |  ¾ÆÀ̵ð½Åû  |  ID/PASSã±â  |  
 
HOME > ¸¶ÀÌÁ¸ > ³ªÀǹ®ÀÇ
ÀÛ ¼º ÀÚ Yantic
ÀÛ ¼º ÀÏ 2020-10-01 ¿ÀÀü 3:28:03
Á¦     ¸ñ Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy
³»     ¿ë Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ (Tenofovir Alafenamide) - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy ¬á¬â¬Ö¬Õ¬ã¬ä¬Ñ¬Ó¬Ý¬ñ¬Ö¬ä ¬ã¬à¬Ò¬à¬Û ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ö ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬à, ¬á¬â¬Ö¬Õ¬ß¬Ñ¬Ù¬ß¬Ñ¬é¬Ö¬ß¬ß¬à¬Ö ¬Õ¬Ý¬ñ ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬ñ ¬ä¬Ñ¬Ü¬Ú¬ç ¬Ù¬Ñ¬Ò¬à¬Ý¬Ö¬Ó¬Ñ¬ß¬Ú¬Û, ¬Ü¬Ñ¬Ü ¬³¬±¬ª¬¥ ¬Ú¬ß¬æ¬Ö¬Ü¬è¬Ú¬ñ ¬Ú ¬ç¬â¬à¬ß¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Û ¬Ô¬Ö¬á¬Ñ¬ä¬Ú¬ä ¬£.
¬¶¬à¬â¬Þ¬Ñ ¬Ó¬í¬á¬å¬ã¬Ü¬Ñ ¬Ú ¬ã¬à¬ã¬ä¬Ñ¬Ó
¬£¬í¬á¬å¬ã¬Ü ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬à¬ã¬å¬ë¬Ö¬ã¬ä¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬Ó ¬Ó¬Ú¬Õ¬Ö ¬ä¬Ñ¬Ò¬Ý¬Ö¬ä¬à¬Ü, ¬Ú¬Þ¬Ö¬ð¬ë¬Ú¬ç ¬ß¬Ñ ¬ã¬Ó¬à¬Ö¬Û ¬á¬à¬Ó¬Ö¬â¬ç¬ß¬à¬ã¬ä¬Ú ¬ã¬á¬Ö¬è¬Ú¬Ñ¬Ý¬î¬ß¬å¬ð ¬à¬Ò¬à¬Ý¬à¬é¬Ü¬å. ¬¶¬à¬â¬Þ¬Ñ ¬ä¬Ñ¬Ò¬Ý¬Ö¬ä¬à¬Ü ¬ä¬â¬Ö¬å¬Ô¬à¬Ý¬î¬ß¬Ñ¬ñ. ¬¬¬Ñ¬Ø¬Õ¬Ñ¬ñ ¬ã¬ä¬à¬â¬à¬ß¬Ñ ¬Ú¬Þ¬Ö¬Ö¬ä ¬à¬ã¬à¬Ò¬å¬ð ¬Ô¬â¬Ñ¬Ó¬Ú¬â¬à¬Ó¬Ü¬å ¬á¬â¬à¬Ú¬Ù¬Ó¬à¬Õ¬Ú¬ä¬Ö¬Ý¬ñ. ¬£¬í¬á¬å¬ã¬Ü ¬á¬â¬à¬Ú¬Ù¬Ó¬à¬Õ¬Ú¬ä¬ã¬ñ ¬á¬Ñ¬é¬Ü¬Ñ¬Þ¬Ú ¬Ó ¬Ü¬Ñ¬â¬ä¬à¬ß¬ß¬í¬ç ¬Ü¬à¬â¬à¬Ò¬Ü¬Ñ¬ç. ¬¯¬Ñ Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ (Tenofovir Alafenamide) - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy ¬è¬Ö¬ß¬Ñ, ¬å¬Ü¬Ñ¬Ù¬Ñ¬ß¬ß¬Ñ¬ñ ¬ß¬Ñ ¬ß¬Ñ¬ê¬Ö¬Þ ¬ã¬Ñ¬Û¬ä¬Ö, ¬Ñ¬Ü¬ä¬å¬Ñ¬Ý¬î¬ß¬Ñ. ¬°¬ã¬ß¬à¬Ó¬ß¬à¬Ö ¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó¬à ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Õ¬Ú¬Ù¬à¬á¬â¬à¬Ü¬ã¬Ú¬Ý ¬æ¬å¬Þ¬Ñ¬â¬Ñ¬ä. ¬³¬â¬Ö¬Õ¬Ú ¬Õ¬à¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬í¬ç ¬Þ¬à¬Ø¬ß¬à ¬à¬ä¬Þ¬Ö¬ä¬Ú¬ä¬î: ¬Þ¬à¬ß¬à¬Ô¬Ú¬Õ¬â¬Ñ¬ä ¬Ý¬Ñ¬Ü¬ä¬à¬Ù¬í; ¬Ñ¬ï¬â¬à¬ã¬Ú¬Ý; ¬è¬Ö¬Ý¬Ý¬ð¬Ý¬à¬Ù¬å. ¬°¬Ò¬à¬Ý¬à¬é¬Ü¬Ñ ¬Ó¬Ü¬Ý¬ð¬é¬Ñ¬Ö¬ä ¬Ó ¬ã¬Ö¬Ò¬ñ ¬ä¬Ñ¬Ü¬Ú¬Ö ¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó¬Ñ, ¬Ü¬Ñ¬Ü ¬Ô¬Ú¬á¬â¬à¬Þ¬Ö¬Ý¬Ý¬à¬Ù¬Ñ, ¬Ñ ¬ä¬Ñ¬Ü¬Ø¬Ö ¬Õ¬Ú¬à¬Ü¬ã¬Ú¬Õ ¬ä¬Ú¬ä¬Ñ¬ß¬Ñ ¬Ú ¬Ü¬â¬Ñ¬ã¬Ú¬ä¬Ö¬Ý¬î ¬Ø¬Ö¬Ý¬Ö¬Ù¬Ñ. ¬¦¬ã¬Ý¬Ú ¬Ó¬í ¬ç¬à¬ä¬Ú¬ä¬Ö ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ (Tenofovir Alafenamide) - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy ¬Ü¬å¬á¬Ú¬ä¬î ¬à¬ã¬ä¬Ñ¬Ó¬Ý¬ñ¬Û¬ä¬Ö ¬Ù¬Ñ¬ñ¬Ó¬Ü¬å ¬ß¬Ñ ¬ã¬Ñ¬Û¬ä¬Ö.
¬±¬â¬Ú¬Þ¬Ö¬ß¬Ö¬ß¬Ú¬Ö
¬±¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬á¬â¬à¬á¬Ú¬ã¬í¬Ó¬Ñ¬ð¬ä ¬á¬Ñ¬è¬Ú¬Ö¬ß¬ä¬Ñ¬Þ, ¬ã¬ä¬â¬Ñ¬Õ¬Ñ¬ð¬ë¬Ú¬Þ ¬à¬ä ¬Ù¬Ñ¬Ò¬à¬Ý¬Ö¬Ó¬Ñ¬ß¬Ú¬ñ ¬£¬ª¬¹ ¬Ú¬ß¬æ¬Ö¬Ü¬è¬Ú¬Ú, ¬Ñ ¬ä¬Ñ¬Ü¬Ø¬Ö ¬à¬ä ¬ç¬â¬à¬ß¬Ú¬é¬Ö¬ã¬Ü¬à¬Ô¬à ¬Ô¬Ö¬á¬Ñ¬ä¬Ú¬ä¬Ñ ¬£. ¬¦¬ã¬Ý¬Ú ¬Ó¬Ñ¬Þ ¬á¬à¬Ü¬Ñ¬Ù¬Ñ¬ß ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ (Tenofovir Alafenamide) - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy ¬ã¬ä¬à¬Ú¬Þ¬à¬ã¬ä¬î ¬å¬Ù¬ß¬Ñ¬ä¬î ¬Ö¬Ô¬à ¬Ú ¬á¬à¬Ý¬å¬é¬Ú¬ä¬î ¬à¬ä¬Ó¬Ö¬ä¬í ¬ß¬Ñ ¬Õ¬â¬å¬Ô¬Ú¬Ö ¬Ó¬à¬á¬â¬à¬ã¬í ¬Ó¬í ¬Þ¬à¬Ø¬Ö¬ä¬Ö ¬á¬à ¬ä¬Ö¬Ý¬Ö¬æ¬à¬ß¬å.
¬±¬Ö¬â¬Ö¬Õ¬à¬Ù¬Ú¬â¬à¬Ó¬Ü¬Ñ
¬³¬Ý¬å¬é¬Ñ¬Ú ¬á¬Ö¬â¬Ö¬Õ¬à¬Ù¬Ú¬â¬à¬Ó¬Ü¬Ú ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬à¬Þ ¬Ö¬ë¬Ö ¬ß¬Ö ¬Ò¬í¬Ý¬Ú ¬Ù¬Ñ¬æ¬Ú¬Ü¬ã¬Ú¬â¬à¬Ó¬Ñ¬ß¬í, ¬à¬Õ¬ß¬Ñ¬Ü¬à, ¬Ö¬ã¬Ý¬Ú ¬á¬Ñ¬è¬Ú¬Ö¬ß¬ä¬à¬Þ ¬Ò¬í¬Ý¬Ñ ¬á¬â¬Ú¬ß¬ñ¬ä¬Ñ ¬á¬à¬Ó¬í¬ê¬Ö¬ß¬ß¬Ñ¬ñ ¬Õ¬à¬Ù¬Ñ, ¬Ú ¬á¬â¬à¬Ú¬Ù¬à¬ê¬Ý¬à ¬å¬ç¬å¬Õ¬ê¬Ö¬ß¬Ú¬Ö ¬ã¬à¬ã¬ä¬à¬ñ¬ß¬Ú¬ñ, ¬ã¬ä¬à¬Ú¬ä ¬ß¬Ö¬Þ¬Ö¬Õ¬Ý¬Ö¬ß¬ß¬à ¬à¬Ò¬â¬Ñ¬ä¬Ú¬ä¬î¬ã¬ñ ¬Ü ¬Ó¬â¬Ñ¬é¬å.
¬±¬â¬à¬ä¬Ú¬Ó¬à¬á¬à¬Ü¬Ñ¬Ù¬Ñ¬ß¬Ú¬ñ
¬¯¬Ö ¬â¬Ö¬Ü¬à¬Þ¬Ö¬ß¬Õ¬å¬Ö¬ä¬ã¬ñ ¬à¬ã¬å¬ë¬Ö¬ã¬ä¬Ó¬Ý¬ñ¬ä¬î ¬á¬â¬Ú¬Ö¬Þ ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬Ò¬à¬Ý¬î¬ß¬í¬Þ: ¬³ ¬á¬à¬é¬Ö¬é¬ß¬à¬Û ¬ß¬Ö¬Õ¬à¬ã¬ä¬Ñ¬ä¬à¬é¬ß¬à¬ã¬ä¬î¬ð; ¬³ ¬Ú¬Þ¬Ö¬ð¬ë¬Ú¬Þ¬Ú¬ã¬ñ ¬Ñ¬Ý¬Ý¬Ö¬â¬Ô¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Þ¬Ú ¬â¬Ö¬Ñ¬Ü¬è¬Ú¬ñ¬Þ¬Ú; ¬£ ¬Ó¬à¬Ù¬â¬Ñ¬ã¬ä¬Ö ¬Õ¬à 18 ¬Ý¬Ö¬ä; ¬¨¬Ö¬ß¬ë¬Ú¬ß¬Ñ¬Þ, ¬ß¬Ñ¬ç¬à¬Õ¬ñ¬ë¬Ú¬Þ¬ã¬ñ ¬ß¬Ñ ¬ã¬ä¬Ñ¬Õ¬Ú¬Ú ¬Ò¬Ö¬â¬Ö¬Þ¬Ö¬ß¬ß¬à¬ã¬ä¬Ú ¬Ú¬Ý¬Ú ¬Ü¬à¬â¬Þ¬Ý¬Ö¬ß¬Ú¬ñ. ¬¦¬ã¬Ý¬Ú ¬á¬Ñ¬â¬Ñ¬Ý¬Ý¬Ö¬Ý¬î¬ß¬à ¬á¬â¬Ú¬ß¬Ú¬Þ¬Ñ¬Ö¬ä¬ã¬ñ ¬Õ¬â¬å¬Ô¬à¬Û ¬Ü¬å¬â¬ã ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó.
¬±¬à¬Ò¬à¬é¬ß¬í¬Ö ¬Õ¬Ö¬Û¬ã¬ä¬Ó¬Ú¬ñ
¬£¬à ¬Ó¬â¬Ö¬Þ¬ñ ¬Ü¬å¬â¬ã¬Ñ ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬Ö ¬Õ¬Ñ¬ß¬ß¬í¬Þ ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬à¬Þ ¬Þ¬à¬Ô¬å¬ä ¬á¬â¬à¬ñ¬Ó¬Ú¬ä¬î¬ã¬ñ ¬ã¬Ý¬Ö¬Õ¬å¬ð¬ë¬Ú¬Ö ¬á¬à¬Ò¬à¬é¬ß¬í¬Ö ¬Õ¬Ö¬Û¬ã¬ä¬Ó¬Ú¬ñ: ¬¤¬à¬Ý¬à¬Ó¬ß¬í¬Ö ¬Ò¬à¬Ý¬Ú, ¬å¬ç¬å¬Õ¬ê¬Ö¬ß¬Ú¬Ö ¬á¬ã¬Ú¬ç¬Ú¬é¬Ö¬ã¬Ü¬à¬Ô¬à ¬ã¬à¬ã¬ä¬à¬ñ¬ß¬Ú¬ñ ¬ß¬Ö¬â¬Ó¬ß¬Ñ¬ñ ¬ã¬Ú¬ã¬ä¬Ö¬Þ¬Ñ. ¬¢¬à¬Ý¬Ú ¬Ó ¬Ø¬Ú¬Ó¬à¬ä¬Ö, ¬ä¬à¬ê¬ß¬à¬ä¬Ñ, ¬Õ¬Ú¬Ñ¬â¬Ö¬ñ ¬Ø¬Ö¬Ý¬å¬Õ¬à¬é¬ß¬à-¬Ü¬Ú¬ê¬Ö¬é¬ß¬í¬Û ¬ä¬â¬Ñ¬Ü¬ä. ¬¡¬Ý¬Ý¬Ö¬â¬Ô¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Ö ¬â¬Ö¬Ñ¬Ü¬è¬Ú¬Ú. ¬°¬Õ¬í¬ê¬Ü¬Ñ. ¬´¬Ñ¬Ü¬Ø¬Ö ¬à¬ä¬Þ¬Ö¬é¬Ñ¬Ö¬ä¬ã¬ñ ¬á¬à¬Ó¬í¬ê¬Ö¬ß¬ß¬Ñ¬ñ ¬å¬ä¬à¬Þ¬Ý¬ñ¬Ö¬Þ¬à¬ã¬ä¬î, ¬ã¬à¬ß¬Ý¬Ú¬Ó¬à¬ã¬ä¬î ¬Ú ¬Ó¬à¬Ù¬Þ¬à¬Ø¬ß¬à¬ã¬ä¬î ¬á¬â¬à¬ñ¬Ó¬Ý¬Ö¬ß¬Ú¬ñ ¬Ó¬í¬ã¬í¬á¬Ñ¬ß¬Ú¬Û ¬ß¬Ñ ¬Ü¬à¬Ø¬Ö. ¬¦¬ã¬Ý¬Ú ¬Ó¬ã¬Ö ¬Ó¬í¬ê¬Ö¬á¬Ö¬â¬Ö¬é¬Ú¬ã¬Ý¬Ö¬ß¬ß¬à¬Ö ¬á¬â¬à¬ñ¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬ß¬Ñ ¬á¬Ö¬â¬Ó¬í¬ç ¬ã¬ä¬Ñ¬Õ¬Ú¬ñ¬ç, ¬ä¬à ¬á¬â¬Ú¬Ö¬Þ ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬Þ¬à¬Ø¬ß¬à ¬á¬â¬à¬Õ¬à¬Ý¬Ø¬Ú¬ä¬î. ¬¦¬ã¬Ý¬Ú ¬Ø¬Ö ¬ã¬à¬ã¬ä¬à¬ñ¬ß¬Ú¬Ö ¬á¬â¬à¬Õ¬à¬Ý¬Ø¬Ñ¬Ö¬ä ¬å¬ç¬å¬Õ¬ê¬Ñ¬ä¬î¬ã¬ñ, ¬ä¬à ¬ã¬ä¬à¬Ú¬ä ¬à¬ã¬ä¬Ñ¬ß¬à¬Ó¬Ú¬ä¬î ¬á¬â¬Ú¬Ö¬Þ ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬Ú ¬à¬Ò¬â¬Ñ¬ä¬Ú¬ä¬î¬ã¬ñ ¬Ù¬Ñ ¬Ü¬à¬ß¬ã¬å¬Ý¬î¬ä¬Ñ¬è¬Ú¬Ö¬Û ¬Ü ¬Ó¬â¬Ñ¬é¬å. ¬°¬Ò¬í¬é¬ß¬à ¬á¬â¬à Nexataf (¬´¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬¡¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25¬Þ¬Ô) - ¬¯¬Ö¬Ü¬ã¬Ñ¬ä¬Ñ¬æ (Tenofovir Alafenamide) - ¬¡¬ß¬Ñ¬Ý¬à¬Ô ¬£¬Ö¬Þ¬Ý¬Ú¬Õ¬Ú/Vemlidy ¬à¬ä¬Ù¬í¬Ó¬í ¬á¬Ñ¬è¬Ú¬Ö¬ß¬ä¬å ¬à¬ã¬ä¬Ñ¬Ó¬Ý¬ñ¬ð¬ä ¬á¬à¬Ý¬à¬Ø¬Ú¬ä¬Ö¬Ý¬î¬ß¬í¬Ö.
¬·¬â¬Ñ¬ß¬Ö¬ß¬Ú¬Ö ¬Ú ¬á¬â¬à¬Õ¬Ñ¬Ø¬Ñ
¬±¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬â¬Ö¬Ü¬à¬Þ¬Ö¬ß¬Õ¬å¬Ö¬ä¬ã¬ñ ¬ç¬â¬Ñ¬ß¬Ú¬ä¬î ¬Ó ¬ã¬å¬ç¬à¬Þ ¬Ú ¬ß¬Ö¬Õ¬à¬ã¬ä¬å¬á¬ß¬à¬Þ ¬Õ¬Ý¬ñ ¬Õ¬Ö¬ä¬Ö¬Û ¬Þ¬Ö¬ã¬ä¬Ö. ¬³¬â¬à¬Ü ¬Ô¬à¬Õ¬ß¬à¬ã¬ä¬Ú ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ô¬à ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬Ñ ¬ã¬à¬ã¬ä¬Ñ¬Ó¬Ý¬ñ¬Ö¬ä ¬Õ¬Ó¬Ñ ¬Ô¬à¬Õ¬Ñ. ¬±¬â¬à¬Õ¬Ñ¬Ø¬Ñ ¬à¬ã¬å¬ë¬Ö¬ã¬ä¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬á¬à ¬â¬Ö¬è¬Ö¬á¬ä¬å ¬Ó¬â¬Ñ¬é¬Ñ, ¬á¬à¬ï¬ä¬à¬Þ¬å ¬á¬â¬Ö¬Ø¬Õ¬Ö, ¬é¬Ö¬Þ ¬Ú¬Õ¬ä¬Ú ¬Ó ¬Ñ¬á¬ä¬Ö¬Ü¬å ¬Ù¬Ñ ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à¬Þ, ¬ß¬å¬Ø¬ß¬à ¬ã¬ß¬Ñ¬é¬Ñ¬Ý¬Ñ ¬á¬à¬ã¬Ö¬ä¬Ú¬ä¬î ¬Ò¬à¬Ý¬î¬ß¬Ú¬è¬å, ¬ã¬Õ¬Ñ¬ä¬î ¬Ó¬ã¬Ö ¬ß¬Ö¬à¬Ò¬ç¬à¬Õ¬Ú¬Þ¬í¬Ö ¬Ñ¬ß¬Ñ¬Ý¬Ú¬Ù¬í, ¬á¬â¬à¬Û¬ä¬Ú ¬à¬Ò¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬Ö ¬Ú ¬á¬à¬Ý¬å¬é¬Ú¬ä¬î ¬Ü¬å¬â¬ã ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬ñ ¬ã ¬ã¬à¬à¬ä¬Ó¬Ö¬ä¬ã¬ä¬Ó¬å¬ð¬ë¬Ú¬Þ ¬â¬Ö¬è¬Ö¬á¬ä¬à¬Þ ¬à¬ä ¬Ó¬â¬Ñ¬é¬Ñ. ¬¯¬Ñ ¬á¬â¬à¬ä¬ñ¬Ø¬Ö¬ß¬Ú¬Ú ¬Ó¬ã¬Ö¬Ô¬à ¬Ü¬å¬â¬ã¬Ñ ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬ñ ¬ß¬Ö¬à¬Ò¬ç¬à¬Õ¬Ú¬Þ¬à ¬â¬Ö¬Ô¬å¬Ý¬ñ¬â¬ß¬à ¬á¬â¬à¬ç¬à¬Õ¬Ú¬ä¬î ¬Õ¬à¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬í¬Ö ¬à¬Ò¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬ñ. ¬£ ¬â¬Ö¬Ù¬å¬Ý¬î¬ä¬Ñ¬ä¬Ö ¬Ó¬â¬Ñ¬é¬à¬Þ ¬Þ¬à¬Ø¬Ö¬ä ¬Ò¬í¬ä¬î ¬á¬à¬ß¬Ú¬Ø¬Ö¬ß¬Ñ ¬Õ¬à¬Ù¬Ú¬â¬à¬Ó¬Ü¬Ñ ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ ¬Ú¬Ý¬Ú ¬Ù¬Ñ¬Þ¬Ö¬ß¬Ñ ¬Ö¬Ô¬à ¬ß¬Ñ ¬Ñ¬ß¬Ñ¬Ý¬à¬Ô ¬Ó ¬ã¬Ý¬å¬é¬Ñ¬Ö, ¬Ö¬ã¬Ý¬Ú ¬ß¬Ú¬Ü¬Ñ¬Ü¬Ú¬ç ¬Ú¬Ù¬Þ¬Ö¬ß¬Ö¬ß¬Ú¬Û ¬Ó ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Þ¬Ö ¬ß¬Ö ¬á¬â¬à¬Ú¬ã¬ç¬à¬Õ¬Ú¬ä

¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬Ü¬å¬á¬Ú¬ä¬î
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬Ü¬å¬á¬Ú¬ä¬î ¬Þ¬à¬ã¬Ü¬Ó¬Ñ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬à¬ä¬Ù¬í¬Ó¬í
¬Ó¬Ú¬â¬ä¬Ñ¬æ ¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â¬Ñ ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25 ¬Þ¬Ô
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ +¬á¬â¬Ú ¬Ô¬Ö¬á¬Ñ¬ä¬Ú¬ä¬Ö d
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬è¬Ö¬ß¬Ñ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬Ú¬ß¬ã¬ä¬â¬å¬Ü¬è¬Ú¬ñ
¬Ü¬å¬á¬Ú¬ä¬î ¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ hepbest
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬Ñ¬ß¬ß¬à¬ä¬Ñ¬è¬Ú¬ñ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬æ¬à¬â¬å¬Þ
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ ¬Ü¬å¬á¬Ú¬ä¬î ¬ã¬Ñ¬ß¬Ü¬ä ¬á¬Ö¬ä¬Ö¬â¬Ò¬å¬â¬Ô
¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ 25 ¬Þ¬Ô
hepbest
hepbest ¬Ü¬å¬á¬Ú¬ä¬î
¬Ü¬å¬á¬Ú¬ä¬î ¬ä¬Ö¬ß¬à¬æ¬à¬Ó¬Ú¬â ¬Ñ¬Ý¬Ñ¬æ¬Ö¬ß¬Ñ¬Þ¬Ú¬Õ hepbest
hepbest 25 mg
tenofovir alafenamide hepbest
tafnat
Š„¾…‰ˆ
tafero ¬Ü¬å¬á¬Ú¬ä¬î
tafsure
¬Ü¬å¬á¬Ú¬ä¬î tafsure